Cases & Deals

  • Home
  • Practices
  • Exonhit (now Diaxonhit) acquires leading independent distributor of in-vitro diagnostics in French market, InGen BioSciences

Share

Exonhit (now Diaxonhit) acquires leading independent distributor of in-vitro diagnostics in French market, InGen BioSciences

December 2012

Client(s) Exonhit S.A. (now Diaxonhit)

Jones Day advised Exonhit SA (now Diaxonhit), a French leader in the field of in-vitro diagnostic listed on the Alternext market of NYSE Euronext Paris, in connection with the €18 million (US$22.9 million) acquisition of InGen BioSciences, the leading independent distributor of in-vitro diagnostics in the French market.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.